It is not yet known whether the current Covid-19 vaccines are effective against the Omicron variant of the coronavirus, or whether they will need to be adapted, says Rolf Sass Sørensen, vice president of investor relations at Bavarian Nordic, to MarketWire.
"So far, the data we have seen shows that we have been able to offer just as much protection for variants as within the original strain. There has been no difference," he says, adding:
More from MedWatch
Experiences from Danish climate partnerships are among the tools that can be leveraged when Novo Nordisk CEO Lars Fruergaard begins stepping up efforts in the life science sector’s central organs in Brussels. ”I’ve been fired up by the intimacy and shared vision we could see in Denmark,” he tells MedWatch.